These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11013761)

  • 1. Inhibitors of HIV-1 reverse transcriptase.
    Parniak MA; Sluis-Cremer N
    Adv Pharmacol; 2000; 49():67-109. PubMed ID: 11013761
    [No Abstract]   [Full Text] [Related]  

  • 2. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
    Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
    Kuritzkes DR
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
    [No Abstract]   [Full Text] [Related]  

  • 4. Transmission of zidovudine resistant strains of HIV-1: the first wave.
    Blower S
    AIDS; 2001 Nov; 15(17):2317-8. PubMed ID: 11698706
    [No Abstract]   [Full Text] [Related]  

  • 5. Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors.
    Torti C; Pozniak A; Nelson M; Hertogs K; Gazzard BG
    J Antimicrob Chemother; 2001 Jul; 48(1):113-6. PubMed ID: 11418520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient.
    de Ronde A; van Dooren M; de Rooij E; van Gemen B; Lange J; Goudsmit J
    AIDS; 2000 Nov; 14(16):2632-3. PubMed ID: 11101087
    [No Abstract]   [Full Text] [Related]  

  • 7. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 8. The daunting challenge of keeping HIV suppressed.
    Cohen J
    Science; 1997 Jul; 277(5322):32-3. PubMed ID: 9229768
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiretroviral treatment and resistance].
    Gómez-Cano M; Villalba N; Mas A; Holguín A; Soriano V
    Rev Clin Esp; 1997 Aug; 197(8):574-82. PubMed ID: 9312796
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
    Vanhems P; Gaudet R; Hirschel B; Imrie A; Conway B; Rouleau D; Vizzard J; Perrin L; Cooper DA; Yerly S
    AIDS; 2000 May; 14(8):1065-7. PubMed ID: 10853993
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs.
    Yahi N; Tourrès C; Tivoli N; Colson P; Dhiver C; Quinson AM; Tamalet C
    AIDS; 2000 Dec; 14(18):2943-5. PubMed ID: 11153678
    [No Abstract]   [Full Text] [Related]  

  • 16. Reverse transcriptase fidelity and HIV-1 variation.
    Keulen W; Nijhuis M; Schuurman R; Berkhout B; Boucher C
    Science; 1997 Jan; 275(5297):229; author reply 230-1. PubMed ID: 8999550
    [No Abstract]   [Full Text] [Related]  

  • 17. Reverse transcriptase fidelity and HIV-1 variation.
    Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
    Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
    Hazen RJ; Harvey RJ; St Clair MH; Ferris RG; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Romines KR; Chan JH; Boone LR
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4465-73. PubMed ID: 16251284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.